2. Apoptosis MAPK/ERK Pathway NF-κB Immunology/Inflammation
  3. Apoptosis MAP4K NF-κB COX
  4. Octahydrocurcumin

Octahydrocurcumin  (Synonyms: Hexahydrobisdemethoxycurcumin)

Cat. No.: HY-N0894 Purity: 99.25%
COA
SDS
Handling Instructions Technical Support

Octahydrocurcumin (Hexahydrobisdemethoxycurcumin) is an orally active anticancer and anti-inflammatory agent, and is the final hydrogenated metabolite of Curcumin (HY-N0005) in vivo. Octahydrocurcumin exerts its anti-tumor and anti-inflammatory effects by inducing the mitochondrial apoptosis pathway and inhibiting the TAK1-NF-κB-COX-2 pathway, respectively.

For research use only. We do not sell to patients.

Octahydrocurcumin

Octahydrocurcumin Chemical Structure

CAS No. : 36062-07-4

Size Price Stock Quantity
Solid or liquid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
 In-stock
Solution
10 mM * 1 mL in DMSO In-stock
Solid or liquid
5 mg In-stock
10 mg In-stock
25 mg In-stock
50 mg In-stock
100 mg In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Other Forms of Octahydrocurcumin:

Octahydrocurcumin Related Antibodies

Top Publications Citing Use of Products

1 Publications Citing Use of MCE Octahydrocurcumin

View All MAP4K Isoform Specific Products:

View All Isoforms
MAP4K2/GCK MAP4K3/GLK MAP4K4/HGK MAP4K5/KHS1 MAP4K6/MINK1 MAP4K7/TNIK MAP4K1/HPK1

View All NF-κB Isoform Specific Products:

View All Isoforms
NF-κB NF-κB1/p50 RelA/p65 RelB c-Rel

View All COX Isoform Specific Products:

View All Isoforms
COX COX-1 COX-2 COX-3

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Octahydrocurcumin (Hexahydrobisdemethoxycurcumin) is an orally active anticancer and anti-inflammatory agent, and is the final hydrogenated metabolite of Curcumin (HY-N0005) in vivo. Octahydrocurcumin exerts its anti-tumor and anti-inflammatory effects by inducing the mitochondrial apoptosis pathway and inhibiting the TAK1-NF-κB-COX-2 pathway, respectively[1][2].

IC50 & Target[2]

COX-2

 

TAK1

 

In Vivo

Octahydrocurcumin (5-20 mg/kg; i.g.; daily; 7 days) exerts potent dose-dependent anti-HCC activity in H22 ascites tumor-bearing mice, with 20 mg/kg OHC increasing survival by 78.98%, reducing ascites volume and cancer cell viability, inducing apoptosis, and modulating mitochondrial pathway-related proteins more effectively than 100 mg/kg curcumin, without immune organ toxicity[1].
Octahydrocurcumin (10-40 mg/kg; i.g.; daily; 7 days) dose-dependently inhibits xylene-induced mouse ear edema, achieving a maximum suppression rate of 70.67% at 40 mg/kg[2].
Octahydrocurcumin (10-40 mg/kg; i.g.; daily; 7 days) dose-dependently reduces acetic acid-induced vascular permeability in mice, reaching a 48.0% suppression rate at 40 mg/kg[2].
Octahydrocurcumin (10-40 mg/kg; i.g.; daily; 7 days) dose-dependently inhibits Carrageenan (HY-125474)-induced mouse paw edema, reduces pro-inflammatory mediator production, selectively suppresses COX-2 expression, and blocks the TAK1-NF-κB pathway[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Kunming (KM) (male, 18-22 g, intraperitoneal injection of H22 cell suspension to establish HCC ascites model)[1]
Dosage: 5 mg/kg; 10 mg/kg; 20 mg/kg
Administration: i.g.; daily; 7 days
Result: Increased survival rates by 26.13%, 50%, and 78.98% respectively compared to vehicle control; 20 mg/kg dose resulted in a significantly higher survival rate than 100 mg/kg curcumin.
Suppressed increases in body weight and abdominal circumference compared to vehicle control; 20 mg/kg dose resulted in significantly lower body weight and abdominal circumference than 100 mg/kg curcumin on day 7.
Showed no significant difference in spleen and thymus indexes compared to intact, vehicle, and curcumin groups at 20 mg/kg dose.
Reduced ascites volume significantly more than 100 mg/kg curcumin at 20 mg/kg dose.
Reduced cancer cellular viability significantly more than 100 mg/kg curcumin at 20 mg/kg dose.
Significantly increased the apoptotic rate of ascitic cells compared to 100 mg/kg curcumin at 20 mg/kg dose.
Upregulated p53, Bax, Bad, cytochrome C, cleaved caspase-9, cleaved caspase-3, and cleaved PARP protein expressions, and downregulated MDM2, Bcl-2, and Bcl-xl protein expressions to a greater extent than 100 mg/kg curcumin at 20 mg/kg dose; also upregulated Bax mRNA and downregulated Bcl-2 mRNA expression.
Animal Model: ICR mice (male and female, 18-22 g)[2]
Dosage: 10 mg/kg; 20 mg/kg; 40 mg/kg
Administration: i.g.; daily; 7 days
Result: Inhibited ear edema with suppression rates of 37.33%, 57.33%, and 70.67% at 10, 20, and 40 mg/kg, respectively.\nInhibited vascular permeability with a maximum suppression ratio of 48.0% at 40 mg/kg.\nAttenuated paw edema dose-dependently from 1 to 6 hours post-carrageenan injection.
Exhibited edema inhibition ratios of 35.87% at 4 hours, 45.16% at 5 hours, and 53.41% at 6 hours at 40 mg/kg.
Significantly reduced carrageenan-induced increases in IL-1β, IL-6, TNF-α, and PGE2 levels at 40 mg/kg, with greater inhibitory activity than curcumin.
Selectively downregulated COX-2 gene and protein expression without affecting COX-1 at 40 mg/kg.
Inhibited TAK1 phosphorylation, reduced TAB1 protein expression, suppressed IKKβ and IκBα phosphorylation, and prevented NF-κB (p65) translocation from the cytosol to the nucleus at 40 mg/kg.
Molecular Weight

376.44

Formula

C21H28O6
CAS No.
Appearance

Solid-Liquid Mixture

Color

Light yellow to yellow

SMILES

OC(CC(O)CCC1=CC=C(O)C(OC)=C1)CCC2=CC=C(O)C(OC)=C2
Structure Classification
Initial Source
Shipping

Room temperature in continental US; may vary elsewhere.
Storage
Pure form -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
Solvent & Solubility
In Vitro: 

DMSO : 100 mg/mL (265.65 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Ethanol : 10 mg/mL (26.56 mM; Need ultrasonic)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 2.6565 mL 13.2823 mL 26.5647 mL
5 mM 0.5313 mL 2.6565 mL 5.3129 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: ≥ 3.75 mg/mL (9.96 mM); Clear solution

    This protocol yields a clear solution of ≥ 3.75 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (37.5 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

    Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
  • Protocol 2

    Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

    Solubility: ≥ 3.75 mg/mL (9.96 mM); Clear solution

    This protocol yields a clear solution of ≥ 3.75 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (37.5 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

    Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
%
DMSO +
% 
+
%
Tween-80 +
%
Saline
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Calculation results:
Working solution concentration: mg/mL
Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).
The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
 If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
References

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
Ethanol / DMSO 1 mM 2.6565 mL 13.2823 mL 26.5647 mL 66.4116 mL
5 mM 0.5313 mL 2.6565 mL 5.3129 mL 13.2823 mL
10 mM 0.2656 mL 1.3282 mL 2.6565 mL 6.6412 mL
15 mM 0.1771 mL 0.8855 mL 1.7710 mL 4.4274 mL
20 mM 0.1328 mL 0.6641 mL 1.3282 mL 3.3206 mL
25 mM 0.1063 mL 0.5313 mL 1.0626 mL 2.6565 mL
DMSO 30 mM 0.0885 mL 0.4427 mL 0.8855 mL 2.2137 mL
40 mM 0.0664 mL 0.3321 mL 0.6641 mL 1.6603 mL
50 mM 0.0531 mL 0.2656 mL 0.5313 mL 1.3282 mL
60 mM 0.0443 mL 0.2214 mL 0.4427 mL 1.1069 mL
80 mM 0.0332 mL 0.1660 mL 0.3321 mL 0.8301 mL
100 mM 0.0266 mL 0.1328 mL 0.2656 mL 0.6641 mL
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Octahydrocurcumin Related Classifications

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Octahydrocurcumin36062-07-4HexahydrobisdemethoxycurcuminApoptosisMAP4KNF-κBCOXMAPK Kinase Kinase KinaseNuclear factor-κBNuclear factor-kappaBCyclooxygenaseBcl-2caspase-9caspase-3Bcl-xlp53BadBaxPARPICR miceMDM2Inhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Octahydrocurcumin
Cat. No.:
HY-N0894
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (396 KB) Français - FR (396 KB) Deutsch - DE (396 KB) Norwegian - NO (396 KB) Español - ES (396 KB) Swedish - SV (396 KB) Italian - IT (396 KB) Korean - KR (396 KB) Portuguese - PT (396 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.